Akoya Biosciences Q2 2024 GAAP EPS $(0.27), Inline, Sales $23.164M Miss $23.552M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akoya Biosciences (NASDAQ:AKYA) reported Q2 2024 GAAP EPS of $(0.27), meeting analyst expectations. However, the company missed its sales estimate, reporting $23.164 million in revenue, a 1.65% shortfall from the $23.552 million estimate and a 1.52% decrease from the same period last year.
August 05, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akoya Biosciences reported Q2 2024 GAAP EPS of $(0.27), meeting expectations, but missed sales estimates with $23.164 million, a 1.65% shortfall and a 1.52% decrease YoY.
While Akoya Biosciences met EPS expectations, the miss on sales estimates and the year-over-year decline in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100